Arcellx, Inc. (ACLX) Covered Calls

Arcellx is a clinical-stage biotechnology company developing innovative cell therapies for cancer and autoimmune diseases. The company utilizes its proprietary D-Domain technology and ARC-SparX platform to engineer controllable and adaptive CAR-T cell therapies. Its lead candidate, anitocabtagene autoleucel (anito-cel), is being co-developed with Kite Pharma for the treatment of relapsed or refractory multiple myeloma, aiming to improve safety and efficacy over existing treatments.

You can sell covered calls on Arcellx, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ACLX (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Arcellx, Inc. (ACLX) is a pioneering biopharmaceutical company at the forefront of the next generation of adoptive cell therapies. The company’s core technology is the D-Domain, a novel, synthetic antigen-binding domain designed to overcome the limitations of traditional scFv-based CAR-T therapies. This technology is deployed across two primary platforms: the ddCAR platform, which creates highly specific and potent therapies, and the ARC-SparX platform, which allows for the precise control of CAR-T cell activity through the administration of soluble protein adapters. This "switchable" functionality is intended to mitigate toxicity and enhance the durability of treatment.

As of March 2026, Arcellx is in the process of being acquired by Gilead Sciences in a deal valued at several billion dollars. The acquisition is a strategic move to integrate Arcellx’s lead program, anitocabtagene autoleucel (anito-cel), into Gilead’s cell therapy portfolio. Anito-cel is currently in Phase 2 clinical trials for relapsed or refractory multiple myeloma and has demonstrated a competitive clinical profile, including high response rates and a manageable safety profile. Arcellx maintains a state-of-the-art manufacturing facility in Pennsylvania, which supports its clinical development and prepares the groundwork for eventual commercial-scale production.

Competitive Landscape

Arcellx operates in the highly specialized and competitive CAR-T therapy market, specifically within the B-cell maturation antigen (BCMA) targeting space. Its most direct competitors developing similar cell therapies for multiple myeloma include Bristol-Myers Squibb and Johnson & Johnson, both of which have approved BCMA-directed CAR-T products. These established players possess significant commercial infrastructure and manufacturing scale.

In the broader biotech and immunotherapy sector, Arcellx tracks against other innovative cell therapy firms like Summit Therapeutics and BridgeBio Pharma. The company also competes for investment and talent with diversified biopharmaceutical leaders such as AbbVie and its soon-to-be parent company, Gilead Sciences. Despite the pending merger, Arcellx’s proprietary binding technology remains a key differentiator against traditional "locked" CAR-T designs used by many of its peers.

Strategic Outlook and Innovation

The company’s 2026 outlook is dominated by the integration process with Gilead and the progression of the iMMagine-1 Phase 2 clinical trial. The strategic goal is to maximize the long-term potential of the anito-cel program by leveraging Gilead’s global commercial reach and the cell therapy expertise of Kite Pharma. Innovation efforts are focused on expanding the D-Domain technology into solid tumors and autoimmune indications, where traditional cell therapies have historically faced challenges related to the immunosuppressive tumor microenvironment and off-target effects.

Arcellx is also advancing its earlier-stage pipeline, including the ARC-SparX programs which represent the next evolution in "programmable" medicine. By enabling the titration of cell therapy activity, Arcellx aims to broaden the therapeutic window and allow for the treatment of diseases where safety concerns have previously limited the use of engineered T-cells. With the backing of a major pharmaceutical partner, the company is positioned to transition from a clinical-stage research entity to a central component of a leading global oncology franchise.

Want more examples? ACLS Covered Calls | ACM Covered Calls